期刊文献+
共找到10篇文章
< 1 >
每页显示 20 50 100
抗凝血酶制剂的临床应用 被引量:8
1
作者 赵维莅 《国外医学(输血及血液学分册)》 1999年第2期90-93,共4页
抗凝血酶(antithrombin Ⅲ,AT-Ⅲ)主要由肝脏合成,可直接抑制凝血酶、因子Ⅹa、Ⅸa、Ⅺa及Ⅻa等凝血因子,是凝血过程的重要抑制物。AT-Ⅲ在许多病理情况下皆有降低,从而导致血栓形成, 并在一定程度上与疾病的严重程度与预后相关。随着浓... 抗凝血酶(antithrombin Ⅲ,AT-Ⅲ)主要由肝脏合成,可直接抑制凝血酶、因子Ⅹa、Ⅸa、Ⅺa及Ⅻa等凝血因子,是凝血过程的重要抑制物。AT-Ⅲ在许多病理情况下皆有降低,从而导致血栓形成, 并在一定程度上与疾病的严重程度与预后相关。随着浓缩AT-Ⅲ制剂的成功制备及研究工作的不断深入,其在术后血栓预防、弥散性血管内凝血、肝肾疾病以及骨髓移植等方面具有广阔的应用前景。 展开更多
关键词 凝血酶制剂 临床应用 AT-Ⅲ缺乏症 血栓形成
下载PDF
凝血酶制剂临床应用进展 被引量:1
2
作者 何金昌 魏向阳 杨帆 《中国农村医学》 1997年第6期59-60,共2页
关键词 凝血酶制剂 消化道出血 外科抢救 口腔疾病
下载PDF
凝血酶制剂临床应用新进展
3
作者 何金昌 陈坚贞 《深圳医学》 1996年第6期43-44,共2页
关键词 凝血酶制剂 临床应用
下载PDF
蛇毒类凝血酶制剂与肝毒性药物对血浆纤维蛋白原水平的影响分析 被引量:3
4
作者 颜楠 刁艳君 +1 位作者 韩峰 刘家云 《检验医学与临床》 CAS 2021年第23期3435-3438,共4页
目的探讨临床上两种常用蛇毒类凝血酶制剂与两种肝毒性药物在用药前后对纤维蛋白原(FIB)水平的影响。方法选择2018年10月31日至2020年10月31日空军军医大学附属西京医院收治的200例FIB水平降低(<1.5 g/L)的住院患者为研究对象。将使... 目的探讨临床上两种常用蛇毒类凝血酶制剂与两种肝毒性药物在用药前后对纤维蛋白原(FIB)水平的影响。方法选择2018年10月31日至2020年10月31日空军军医大学附属西京医院收治的200例FIB水平降低(<1.5 g/L)的住院患者为研究对象。将使用蛇毒类凝血酶制剂(白眉蛇毒血凝酶、巴曲酶)的70例患者设为有产物组,使用肝毒性药物[丙戊酸(VAP)、培门冬酶(PEG-ASP)]的130例患者设为无产物组。分别于患者使用药物治疗前后检测常规凝血6项指标的水平变化。结果有产物组中的泌尿外科患者其FIB、D二聚体(D-Dimer)、纤维蛋白/纤维蛋白原降解产物(FDP)水平在未手术未使用白眉蛇毒血凝酶治疗前与手术后、用药治疗后比较,差异有统计学意义(P<0.05)。耳鼻喉科患者的FIB与FDP水平在使用巴曲酶治疗前后比较差异有统计学意义(P<0.05)。无产物组中的神经科患者在使用VAP治疗前后的FIB水平比较,差异有统计学意义(P<0.05);血液科患者在使用PEG-ASP治疗前后的FIB水平比较,差异有统计学意义(P<0.05)。结论FIB水平在使用该4种药物前后的显著差异变化可以为临床提供用药指导参考,避免导致严重低纤维蛋白血症引起的出血风险。 展开更多
关键词 蛇毒类凝血酶制剂 巴曲酶 丙戊酸 培门冬酶 纤维蛋白原 纤维蛋白/纤维蛋白原降解产物
下载PDF
凝血酶原复合物浓缩制剂的临床安全性及药动学观察
5
作者 王学锋 张嵘 +1 位作者 黄霞萍 王鸿利 《临床输血与检验》 CAS 2003年第3期198-199,共2页
关键词 凝血酶原复合物浓缩制剂 安全性 观察 药物动力学
下载PDF
血浆制剂在儿科临床的应用——儿科疾病(16) 被引量:1
6
作者 吴梓梁 《新医学》 北大核心 2008年第10期692-694,共3页
关键词 新鲜冰冻血浆 冷沉淀物 因子Ⅷ浓缩制剂 因子Ⅸ缩制剂 凝血酶原复合物浓缩制剂 凝血酶Ⅲ浓缩制剂 白蛋白制剂
下载PDF
血友病B合并脑外伤一例报告
7
作者 田永吉 甲戈 马振宇 《北京医学》 CAS 2006年第6期350-350,353,共2页
关键词 血友病B 脑外伤 活化部分凝血活酶时间 凝血酶原复合物浓缩制剂 硬膜外血肿 头颅CT 脑内血肿 瞳孔间距 皮下瘀斑 GCS评分
下载PDF
Atrial fibrillation in the elderly 被引量:5
8
作者 Roberto A. Franken Ronaldo F. Rosa Silvio CM Santos 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2012年第2期91-100,共10页
This review discusses atrial fibrillation according to the guidelines of Brazilian Society of Cardiac Arrhythmias and the Brazilian Cardiogeriatrics Guidelines. We stress the thromboembolic burden of atrial fibrillati... This review discusses atrial fibrillation according to the guidelines of Brazilian Society of Cardiac Arrhythmias and the Brazilian Cardiogeriatrics Guidelines. We stress the thromboembolic burden of atrial fibrillation and discuss how to prevent it as well as the best way to conduct cases of atrial fibrillatios in the elderly, reverting the arrhythmia to sinus rhythm, or the option of heart rate control. The new methods to treat atrial fibrillation, such as radiofrequency ablation, new oral direct thrombin inhibitors and Xa factor inhibitors, as well as new antiarrhythmic drugs, are depicted. 展开更多
关键词 Atrial fibrillation Heart failure THROMBO-EMBOLISM TREATMENT PREVENTION
下载PDF
Antithrombotic effects of bromophenol,an alga-derived thrombin inhibitor
9
作者 史大永 李晓红 +3 位作者 李敬 郭书举 苏华 范晓 《Chinese Journal of Oceanology and Limnology》 SCIE CAS CSCD 2010年第1期96-98,共3页
Thrombin,the ultimate proteinase of the coagulation cascade,is an attractive target for the treatment of a variety of cardiovascular diseases.A bromophenol derivative named (+)-3-(2,3-dibromo-4,5-dihydroxy-phenyl)-4-b... Thrombin,the ultimate proteinase of the coagulation cascade,is an attractive target for the treatment of a variety of cardiovascular diseases.A bromophenol derivative named (+)-3-(2,3-dibromo-4,5-dihydroxy-phenyl)-4-bromo-5,6-dihydroxy-1,3-dihydroiso-benzofuran 1,isolated from the brown alga Leathesia nana exhibited significant thrombin inhibitory activity.In this study,we investigated the inhibition of human thrombin in vitro with this bromophenol derivative,and its antithrombotic efficacy in vivo using the arteriovenous shunt model and the ferric chloride-induced arterial thrombosis model in rats.The results show that the bromophenol derivative is a potential inhibitor of thrombin (IC50=1.03 nmol/L).In antithrombotic experiments in vivo,the bromophenol derivative also shows good effect comparing with the control group.These data indicate that the bromophenol derivative is a potential drug for prophylaxis and the treatment of thrombotic diseases. 展开更多
关键词 thrombin inhibitor antithrombotic effect bromophenol derivative
下载PDF
A Review of an Unorthodox Argatroban Infusion Rate for Anticoagulation in a Patient Case
10
作者 Erin Barnett Loesch Christopher Ryan Boldi 《Journal of Pharmacy and Pharmacology》 2017年第4期189-193,共5页
Argatroban is an intravenous DTI (direct synthetic thrombin inhibitor) that is not routinely used for anticoagulation; thus, expertise surrounding its use is very limited. Therefore, this case reviews an unusually h... Argatroban is an intravenous DTI (direct synthetic thrombin inhibitor) that is not routinely used for anticoagulation; thus, expertise surrounding its use is very limited. Therefore, this case reviews an unusually high argatroban infusion rate, which was needed to prevent further emboli formation in a patient. In this case, a 61-year-old Caucasian male patient exhibited heparin resistance during an intraoperative vascular procedure as measured by activated clotting time and PTT (partial thromboplastin time). The patient had multiple occlusions in his right lower extremities and underwent embolectomies of the right popliteal and posterior tibial arteries. The clinical pharmacist was consulted to manage the argatroban infusion once heparin was discontinued. The therapeutic window required a PTr of 1.5-3 times the patient baseline (35-75 s). The patient was reported to be 89 kg with a baseline PTT of 24.7 s and INR (international normalized ratio) of 0.98. The starting dose ofargatroban was initiated by the pharmacist at 2 mcg/kg/min (10.7 mL/h) as the patient did not have hepatic failure or sepsis. The patient was maintained on argatroban in the therapeutic PTT window for more than 72 h; however, frequent and aggressive dose increases, to a final rate of 7.5 mcg/kg/min (40 mL/h), were needed to maintain the therapeutic PTT level. From the case, the cause of heparin resistance still has not been determined despite a hematologic work-up; however, this patient required an unusually high infusion rate of argatroban to maintain a therapeutic PTT during the hospital course before being changed to an anticoagulation regimen for discharge. 展开更多
关键词 ANTICOAGULATION ARGATROBAN direct thrombin inhibitor heparin resistance partial thromboplastin time.
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部